Abstracts tagged "pulmonary"

Abstract Number: 0883 • ACR Convergence 2025
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Ali Ayla¹, Chenyue Huang², Claudia Pedroza³, Meng Zhang⁴, John VanBuren⁵, Flavia Castelino⁶, Lorinda Chung⁷, Luke Evnin⁸, Tracy Frech⁹, Jessica Gordon¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹⁰, Dorota Lebiedz-Odrobina⁵, Yiming Luo¹⁴, Ashima Makol¹⁵, Maureen Mayes¹⁶, Zsuzsanna McMahan¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson²⁰, Nora Sandorfi²¹, Ami Shah¹², Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug¹, Virginia Steen²⁴, Elizabeth Volkmann²⁵, Carleigh Zahn¹³, Wenjin J Zheng², Elana Bernstein¹⁴ and Shervin Assassi²⁶, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁴UTHealth Houston Division of Rheumatology, Houston, ⁵University of Utah, Salt Lake City, UT, ⁶Massachusetts General Hospital, Boston, MA, ⁷Stanford University, Stanford, CA, ⁸Scleroderma Research Foundation, Brisbane, CA, ⁹Vanderbilt University Medical Center, Nashville, TN, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Columbia University, New York, NY, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶UT Health Houston Division of Rheumatology, Houston, TX, ¹⁷UT Health Houston, Houston, TX, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern Memorial Hospital, Chicago, IL, ²⁰Northwestern University, Chicago, IL, ²¹University of Pennsylvania, Philadelphia, PA, ²²Duke University, Durham, NC, ²³National Institutes of Health, Great Falls, VA, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable and difficult to predict using clinical variables alone. Therefore, there…
Abstract Number: 2031 • ACR Convergence 2025
Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
Genna Braverman¹, Kerri Aronson², Charlene Thomas² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell, New York, NY, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is common and important feature of systemic autoimmune rheumatic diseases (SARD). Rheumatologists and pulmonologists are central to the care of…
Abstract Number: 0880 • ACR Convergence 2025
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
Nicholas landini¹, lisa Jungblut², cecilia strappa³, Christian Blüthgen², Rucsandra Dobrota⁴, Muriel Elhai⁵, Carina Mihai⁶, Sinziana Muraru-Carbune², Martina Orlandi⁷, mariaelena Occhipinti⁸, Khadija El-Aoufy⁹, Gemma Lepri¹⁰, valeria panebianco¹¹, anna rita larici³, Anna-Maria Hoffmann-Vold¹², Cosimo Nardi¹³, Serena Guiducci¹⁴, Silvia Bellando-Randone¹⁵, Marco Matucci-Cerinic¹⁶, Thomas Frauenfelder², Oliver Distler¹⁷ and Cosimo Bruni¹⁸, ¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ³Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, rome, Italy, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁶University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ⁸Division of Radiology, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., pisa, Italy, ⁹Department of Health Science, University of Florence, Florence, Italy., firenze, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy., Rome, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. ², University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Florence, Italy, ¹⁴Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ¹⁵University of Florence, Florence, Florence, Italy, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁸University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc), especially in case of extensive disease detected on…
Abstract Number: 2030 • ACR Convergence 2025
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
fredeswinda Romero-Bueno¹, lydia Abasolo Alcazar², Mª Jesus Rodriguez-Nieto³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Laura Cebrian⁵, Belen Lopez Muñiz⁶, Jesus Loarce Martos⁷, Juan A Rigual⁷, Hilda Godoy Tundidor⁸, Rosalia Laporta⁹, Irene Llorente Cubas¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁰ and Olga Sanchez Pernaute¹⁴, ¹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ²IdISSC. HCSC, Madrid, Madrid, Spain, ³Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario puerta de hierro, Madrid, Spain, ⁹Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Clinica Universidad de Navarra, Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is produced by type 2 alveolar epithelial cells. High circulating KL6 levels show a good accuracy in the diagnosis…
Abstract Number: 0457 • ACR Convergence 2025
Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
Pratyusha Banik¹, Melody Andrews¹, Sudhakar Pipavath¹ and Namrata Singh², ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of lung cancer with shared risk factors being heavy smoking history and possibly interstitial…
Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…
Abstract Number: 0433 • ACR Convergence 2025
In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
John Langley¹, Karuna Bista², Clarisse Yapp², Nisha Sapkota³, Shukranta Shrestha² and Sulav Pyakurel¹, ¹Montefiore New Rochelle Hospital, New Rochelle, NY, ²Montefiore New Rochelle Hospital, New Rochelle, ³Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY
Background/Purpose: Although it has been documented that patients with Rheumatoid Arthritis may be at increased risk of Pulmonary Embolism, other inpatient outcomes remain largely unexplored.…
Abstract Number: 1662 • ACR Convergence 2025
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Anna-Maria Hoffmann-Vold¹, Shervin Assassi², Vincent Cottin³, Michael Kreuter⁴, Claudia Valenzuela⁵, Marlies S Wijsenbeek⁶, Hui Gu⁷, Ivana Ritter⁸, Susanne Stowasser⁸, Gerrit Weimann⁸ and Toby M Maher⁹, ¹Oslo University Hospital, Oslo, Norway, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, ⁵Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, ⁶Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles
Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
adela cristina sarbu¹, Liubov Petelytska², lorenzo tofani³, Gianluca Moroncini⁴, Alexandra Balbir-Gurman⁵, elisabetta zanatta⁶, Jörg Henes⁷, paolo airò⁸, Marco Matucci-Cerinic⁹, Ana Maria Gheorghiu¹⁰, antonella marcoccia¹¹, branimir Anić¹², Jelena Colic¹³, Daniel Furst¹⁴, julia Spierings¹⁵, Francesco Del Galdo¹⁶, Britta Maurer¹⁷, Anna-Maria Hoffmann-Vold¹⁸, Oliver Distler¹⁹ and Cosimo Bruni²⁰, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #³, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, ³Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁴Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁵• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, ⁶Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁹University San Raffaele Milano, Milano, Milan, Italy, ¹⁰Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹¹Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, ¹²Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, ¹³Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, ¹⁴Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁵Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹⁶University of Leeds, Leeds, United Kingdom, ¹⁷Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹⁸Oslo University Hospital, Oslo, Norway, ¹⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁰University of Zurich, Zurich, Switzerland
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
Abstract Number: 0224 • ACR Convergence 2025
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Delia Reina¹, Paula Estrada-Alarcón², Daniel Roig-Vilaseca¹, Dacia Cerdà¹, Vanessa Navarro-Angeles³, oscar Camacho¹, Sergi Herdia⁴, Marta lópez-Gómez¹, Silvia Gacía-Díaz¹, Paola Vidal Montal⁵, Pol Maymó-Paituvi⁶, martí Aguilar-Coll⁷ and Javier Narváez⁸, ¹Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology, Complex Universitari Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain, Sant Joan Despí, Barcelona, Spain, ⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, L'Hospitalet; Barcelona, Barcelona, Spain
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…
Abstract Number: 0168 • ACR Convergence 2025
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Liya Sisay Getachew⁶, Mark Chaballa⁷, Vadim Khaychuk⁸, Misti Paudel⁹, Katherine Liao¹⁰ and Jeffrey Sparks⁶, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Pennington, NJ, ⁹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), is a serious extra-articular manifestation of RA that significantly contributes…
Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].